At the evaluation period (week 29-36), the mean and median level of haemoglobin in patients treated with MIRCERA was virtually identical to their baseline haemoglobin level.
Hindamisperioodil (nädalad 29... 36) oli MIRCERA’ ga ravitud patsientide keskmine hemoglobiinisisaldus peaaegu identne algväärtusega.